FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387047327> ?p ?o ?g. }

• W4387047327 abstract "Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling. PMF as well as secondary MF (post-ET and post-PV MF) are the most aggressive MPNs. Presently, there is no curative treatment, except allogenic hematopoietic stem cell transplantation. JAK inhibitors, essentially ruxolitinib, are the therapy of reference for intermediate and high-risk MF. However, presently the current JAK inhibitors behave mainly as anti-inflammatory drugs, improving general symptoms and spleen size without major impact on disease progression. A better understanding of the genetics of MF, the biology of its leukemic stem cells (LSCs), the mechanisms of fibrosis and of cytopenia and the role of inflammatory cytokines has led to new approaches with the development of numerous therapeutic agents that target epigenetic regulation, telomerase, apoptosis, cell cycle, cytokines and signaling. Furthermore, the use of a new less toxic form of interferon-α has been revived, as it is presently one of the only molecules that targets the mutated clone. These new approaches have different aims: (a) to provide alternative therapy to JAK inhibition; (b) to correct cytopenia; and (c) to inhibit fibrosis development. However, the main important goal is to find new disease modifier treatments, which will profoundly modify the progression of the disease without major toxicity. Presently the most promising approaches consist of the inhibition of telomerase and the combination of JAK2 inhibitors (ruxolitinib) with either a BCL2/BCL-xL or BET inhibitor. Yet, the most straightforward future approaches can be considered to be the development of and/or selective inhibition of JAK2V617F and the targeting MPL and calreticulin mutants by immunotherapy. It can be expected that the therapy of MF will be significantly improved in the coming years." @default.
• W4387047327 created "2023-09-27" @default.
• W4387047327 creator A5000559973 @default.
• W4387047327 creator A5031789027 @default.
• W4387047327 creator A5033634773 @default.
• W4387047327 creator A5075283363 @default.
• W4387047327 creator A5077099095 @default.
• W4387047327 creator A5092943550 @default.
• W4387047327 date "2023-09-26" @default.
• W4387047327 modified "2023-10-17" @default.
• W4387047327 title "Recent advances in therapies for primary myelofibrosis" @default.
• W4387047327 cites W1662539477 @default.
• W4387047327 cites W1821109160 @default.
• W4387047327 cites W1970925590 @default.
• W4387047327 cites W1976156018 @default.
• W4387047327 cites W1978853026 @default.
• W4387047327 cites W1989336431 @default.
• W4387047327 cites W2003272442 @default.
• W4387047327 cites W2025476041 @default.
• W4387047327 cites W2045032252 @default.
• W4387047327 cites W2046982014 @default.
• W4387047327 cites W2064453268 @default.
• W4387047327 cites W2070075266 @default.
• W4387047327 cites W2078743099 @default.
• W4387047327 cites W2081473305 @default.
• W4387047327 cites W2086646375 @default.
• W4387047327 cites W2102579732 @default.
• W4387047327 cites W2110444080 @default.
• W4387047327 cites W2116878961 @default.
• W4387047327 cites W2131752437 @default.
• W4387047327 cites W2143668961 @default.
• W4387047327 cites W2146142395 @default.
• W4387047327 cites W2149986474 @default.
• W4387047327 cites W2157143174 @default.
• W4387047327 cites W2163120873 @default.
• W4387047327 cites W2168586801 @default.
• W4387047327 cites W2171835285 @default.
• W4387047327 cites W2195061194 @default.
• W4387047327 cites W2204168032 @default.
• W4387047327 cites W2218840816 @default.
• W4387047327 cites W2230798701 @default.
• W4387047327 cites W2306779733 @default.
• W4387047327 cites W2417685891 @default.
• W4387047327 cites W2493190817 @default.
• W4387047327 cites W2564597498 @default.
• W4387047327 cites W2581414126 @default.
• W4387047327 cites W2586215211 @default.
• W4387047327 cites W2590741349 @default.
• W4387047327 cites W2773899764 @default.
• W4387047327 cites W2775016799 @default.
• W4387047327 cites W2806455593 @default.
• W4387047327 cites W2896385413 @default.
• W4387047327 cites W2900152748 @default.
• W4387047327 cites W2900909304 @default.
• W4387047327 cites W2901309750 @default.
• W4387047327 cites W2901966462 @default.
• W4387047327 cites W2903875419 @default.
• W4387047327 cites W2910997658 @default.
• W4387047327 cites W2912561801 @default.
• W4387047327 cites W2912733475 @default.
• W4387047327 cites W2944617176 @default.
• W4387047327 cites W2944762355 @default.
• W4387047327 cites W2945090381 @default.
• W4387047327 cites W2948635289 @default.
• W4387047327 cites W2948784783 @default.
• W4387047327 cites W2955829639 @default.
• W4387047327 cites W2970457608 @default.
• W4387047327 cites W2976755053 @default.
• W4387047327 cites W2980830065 @default.
• W4387047327 cites W2981465698 @default.
• W4387047327 cites W2988517531 @default.
• W4387047327 cites W2990179403 @default.
• W4387047327 cites W2990269696 @default.
• W4387047327 cites W2997707101 @default.
• W4387047327 cites W3002428524 @default.
• W4387047327 cites W3005420401 @default.
• W4387047327 cites W3006101943 @default.
• W4387047327 cites W3022009389 @default.
• W4387047327 cites W3043513814 @default.
• W4387047327 cites W3045772015 @default.
• W4387047327 cites W3093428864 @default.
• W4387047327 cites W3112914139 @default.
• W4387047327 cites W3133520808 @default.
• W4387047327 cites W3134473205 @default.
• W4387047327 cites W3138777533 @default.
• W4387047327 cites W3140926965 @default.
• W4387047327 cites W3142460753 @default.
• W4387047327 cites W3149662796 @default.
• W4387047327 cites W3169920628 @default.
• W4387047327 cites W3172890748 @default.
• W4387047327 cites W3181435917 @default.
• W4387047327 cites W3187131292 @default.
• W4387047327 cites W3195081224 @default.
• W4387047327 cites W3195336015 @default.
• W4387047327 cites W3196753640 @default.
• W4387047327 cites W3197283914 @default.
• W4387047327 cites W3200542521 @default.
• W4387047327 cites W3204171974 @default.
• W4387047327 cites W3206662804 @default.
• W4387047327 cites W3210746527 @default.

• next